Labcorp Holdings Inc.
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore Labcorp Holdings
Core profile pages, annual revenue records, and related research hubs for this company.
Labcorp Holdings Inc.
Compare market positioning with top industry peers
Explore Labcorp Holdings
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$14.0B
Market Cap
$18.2B
Net Income
$877M
Employees
80,000
Labcorp is executing a strategic pivot back to core central laboratory diagnostics following the complete spin-off of its clinical development business. Under CEO Adam Schechter, the healthcare diagnostics giant generated exactly $12.4 billion in revenue and maintains a $18.2 billion market cap with exactly 80000 employees. The financial narrative in 2026 is entirely defined by aggressive, hospital system partnerships; facing severe reimbursement pressure from Medicare Labcorp is frantically acquiring the unprofitable internal labs of struggling regional health systems, converting them into efficient, high-volume testing hubs.
Revenue Trend Analysis
YoY Change
+7.2%
2-Year CAGR
+7.1%
Peak Year
2025
Trend
Consistent Growth
Labcorp Holdings Inc. has reported revenue across 3 fiscal years, compounding at +7.1% annually over 2 years. The most recent year saw a 7.2% increase versus the prior year. Revenue peaked in 2025 at $14.0B. Out of 2 reported periods, 2 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $14.0B | $877M | +7.2% |
| FY2024 | $13.0B | $746M | +7.0% |
| FY2023 | $12.2B | $418M | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Labcorp Holdings Inc. reported approximately $12.4B in fiscal year 2025 with a team of 80,000 employees worldwide.
Labcorp Holdings Inc. strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Clinical Laboratory Services and Biopharma Laboratory Services is driven by steady cash generation and pricing power, enabling Labcorp Holdings Inc. to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Labcorp Holdings Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/labcorp/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Labcorp Holdings Inc. reported $14B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/labcorp/financials" target="_blank" rel="noopener">CorpDigest — Labcorp Holdings Inc. financials</a></div>